A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

NCT01627054 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

NETWORK

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: AT7519M

Sponsor

NCIC Clinical Trials Group

Collaborators

[object Object]